|
|
The Hectorol Start Card provides your patients with a free 30-day supply of Hectorol capsules.* Patients with private insurance or without insurance coverage can also use it to receive their next 5 refills for $5 each. †
- Activation of Hectorol Start Card requires a new prescription for Hectorol capsules.
- Patient’s insurance determines which side of the card may be used. Medicare/Medicaid and other government-insured patients may use only the voucher side of the card to obtain the free 30-day supply. All other patients may use only the debit side of the card to obtain the free 30-day supply and 5 refills for $5 each. †
- Genzyme is committed to helping your patients achieve their PTH goals. Learn more about the Hectorol 1 mcg Promise.
Contact your Genzyme representative to receive a supply of Hectorol Start Cards for your patients.
For more information on the Hectorol Start Card, call Renassist℗ at 1-800-847-0069.
* Prescriptions for 0.5mcg, 1 mcg, and 2.5 mcg are covered with the Start Card.
† Maximum benefit of the Hectorol Start Card is $200 per refill.
hec_m_safety_info
Important Treatment Considerations
Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 Chronic Kidney Disease (capsules) and in patients with Chronic Kidney Disease on dialysis (capsules and injection). Hectorol is contraindicated in patients with a tendency towards hypercalcemia or current evidence of vitamin D toxicity. Overdosage of any form of vitamin D is dangerous. Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis drugs. Chronic hypercalcemia can lead to generalized vascular and soft tissue calcification. Pharmacologic doses of vitamin D and its derivatives should be withheld during Hectorol treatment to avoid possible additive effects and hypercalcemia. Magnesium-containing antacids and Hectorol should not be administered concomitantly. Adverse effects of Hectorol treatment are: hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of iPTH. Adverse events reported by ≥ 5% of the Hectorol-treated predialysis patients included: infection, chest pain, constipation, dyspepsia, anemia, dehydration, depression, hypertonia, insomnia, paresthesia, increased cough, dyspnea, and rhinitis. Adverse events reported by ≥ 5% of the Hectorol-treated dialysis patients included: headache, malaise, bradycardia, nausea/vomiting, edema, dizziness, dyspnea, and pruritus. See Hectorol Capsules Full Prescribing Information or Hectorol Injection Full Prescribing Information or call Genzyme Medical Information at 1-800-847-0069.
|
|
 |
|
|
|
| Contact |
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600
Email Us
|
 |
|
|
|
|
